BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22948942)

  • 1. miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells.
    Huang S; Guo W; Tang Y; Ren D; Zou X; Peng X
    Oncol Rep; 2012 Nov; 28(5):1831-7. PubMed ID: 22948942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.
    Ren D; Wang M; Guo W; Zhao X; Tu X; Huang S; Zou X; Peng X
    Int J Oncol; 2013 Apr; 42(4):1473-81. PubMed ID: 23404342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.
    Ren D; Wang M; Guo W; Huang S; Wang Z; Zhao X; Du H; Song L; Peng X
    Cell Tissue Res; 2014 Dec; 358(3):763-78. PubMed ID: 25296715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway.
    Chang YL; Zhou PJ; Wei L; Li W; Ji Z; Fang YX; Gao WQ
    Oncotarget; 2015 Sep; 6(27):24017-31. PubMed ID: 26172296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.
    Wang M; Ren D; Guo W; Wang Z; Huang S; Du H; Song L; Peng X
    Int J Oncol; 2014 Jul; 45(1):362-72. PubMed ID: 24805183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice.
    Dou J; He XF; Cao WH; Zhao FS; Wang XY; Liu YR; Wang J
    Cell Mol Biol (Noisy-le-grand); 2013 Oct; Suppl 59():OL1861-8. PubMed ID: 24120113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145.
    Guo W; Ren D; Chen X; Tu X; Huang S; Wang M; Song L; Zou X; Peng X
    J Cell Biochem; 2013 Jul; 114(7):1606-15. PubMed ID: 23355420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
    Fomeshi MR; Ebrahimi M; Mowla SJ; Khosravani P; Firouzi J; Khayatzadeh H
    Cell Mol Biol Lett; 2015 Sep; 20(3):448-65. PubMed ID: 26208390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory action of pristimerin on hypoxia‑mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells.
    Zuo J; Guo Y; Peng X; Tang Y; Zhang X; He P; Li S; Wa Q; Li J; Huang S; Xu D
    Oncol Rep; 2015 Mar; 33(3):1388-94. PubMed ID: 25571882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.
    Yu J; Lu Y; Cui D; Li E; Zhu Y; Zhao Y; Zhao F; Xia S
    Oncol Rep; 2014 Feb; 31(2):910-8. PubMed ID: 24317363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
    Huang S; He P; Peng X; Li J; Xu D; Tang Y
    Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
    Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
    Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.
    Wang L; Song G; Tan W; Qi M; Zhang L; Chan J; Yu J; Han J; Han B
    Oncotarget; 2015 Nov; 6(34):35978-90. PubMed ID: 26451614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HN1L promotes stem cell-like properties by regulating TGF-β signaling pathway through targeting FOXP2 in prostate cancer.
    Nong S; Wang Z; Wei Z; Ma L; Guan Y; Ni J
    Cell Biol Int; 2022 Jan; 46(1):83-95. PubMed ID: 34519127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
    Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
    Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.
    Hsieh IS; Chang KC; Tsai YT; Ke JY; Lu PJ; Lee KH; Yeh SD; Hong TM; Chen YL
    Carcinogenesis; 2013 Mar; 34(3):530-8. PubMed ID: 23188675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
    Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
    Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells.
    Sarkar D; Shields B; Davies ML; Müller J; Wakeman JA
    Int J Cancer; 2012 Jan; 130(2):328-37. PubMed ID: 21365650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
    Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
    Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs and epithelial-mesenchymal transition in prostate cancer.
    Sekhon K; Bucay N; Majid S; Dahiya R; Saini S
    Oncotarget; 2016 Oct; 7(41):67597-67611. PubMed ID: 27588490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.